Minimal disease activity achivement by PsA domain over 2y, in guselkumab phase 3 Everyone goes on about skin efficacy with guselkumab, but pretty good early on for enthesitis & swollen joints too... has challenged my uninformed thinking! POS1067 #EULAR2022 #IL23 @RheumNow https://t.co/chCWeFd05o

🔜 Remission in PsA : the earlier the better ⏰ Dutch cohort (DEPAR) 300+pts Failure to achieve MDA 1yr post diagnosis 🧨worst QoL yr 1️⃣2️⃣&3️⃣ 🧨↗️bioDMARDs use over time 🧨no recovery #OP0028 #EULAR2022 @RheumNow https://t.co/IS6ySIQvBP

Can you train #dermatologists to do ultrasound to detect #PsA if pt has joint pain. POCUS of up to 3 painful joints. US ⬆️derm suspicion of PsA- but this is not feasible in busy offices and no reimbursement @RheumNow #EULAR2022 @eular_org OP0029 https://t.co/9a3gDgIBp0

How do we treat fatigue in our PsA patients? Guselkumab PsA trials showed systemic disease activity/function, joint manifestations, and skin involvement accounted for 62% of variability in fatigue. How do we account for the other 38%? @RheumNow #EULAR2022 ABST#OP0025

#Bestinclass #EULAR2022 #PsA @RheumNow #OP0027 #CVE #MACE with #Tofacitinib in #psoriatic #arthritis and #PsO with median 3 to 4 yrs Rx. 40% metabolic syndrome which is high. There was no comparison. As expected hose with ⬆️MACE risks had more outcomes. https://t.co/sTjFHsUxzi

Rahman et al. Factors associated with fatigue and its improvement in trials IL23i guselkumab. Disease activity/function (34%), joints (16%), skin (12%) but 38.5% of fatigue variability remains unexplained. @RheumNow #EULAR2022 OP0025 https://t.co/C08R0IWM3S https://t.co/QnCvPwEwKS

• EULAR Abstract Archive

Musculoskeletal US used by dermatologists helped increasedspecificity of PsA detection, leading to fewer false suspicions of PsA earlier diagnosis of psoriatic arthritis. @RheumNow #EULAR2022 ABST#OP0029